Development of characterization methods for entacapone in a pharmaceutical bulk

Journal of Pharmaceutical and Biomedical Analysis

Volumn 54, Issue 4, 2011, Pages 860-865

  Soukhova, Nadejda ^a   Kassymbek, Zarema ^a   Bradby, Sanford ^a   Martin Esker, Amanda ^a   White, Patricia ^a   Wahab, Samir ^a  

^a Analytical Research and Development Laboratory   (United States)

Author keywords

Compendial testing; Entacapone; FTIR; Reversed phase HPLC; UV

Indexed keywords

BUFFER; ENTACAPONE; METHANOL; POTASSIUM DIHYDROGEN PHOSPHATE; WATER;

ACCURACY; ANALYTIC METHOD; ARTICLE; ATMOSPHERIC MOISTURE; AVERAGE; CONVALESCENCE; DEGRADATION; DRUG DETERMINATION; DRUG IMPURITY; FLOW RATE; HUMAN; INFRARED RADIATION; INFRARED SPECTROSCOPY; PH; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SENSITIVITY ANALYSIS; STANDARD; ULTRAVIOLET RADIATION; WATER ANALYSIS;

ANTIPARKINSON AGENTS; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG CONTAMINATION; ENZYME INHIBITORS; LIMIT OF DETECTION; MICROCHEMISTRY; NITRILES; QUALITY CONTROL; REPRODUCIBILITY OF RESULTS; SPECTROPHOTOMETRY, ULTRAVIOLET; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TECHNOLOGY, PHARMACEUTICAL; WATER;

EID: 78650250036     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpba.2010.10.019     Document Type: Article

References (13)

1. Männistö P.T., Kaakkola S. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol. Rev. 1999, 51:593-628.
2. Wikberg T., Vuorela A., Ottoila P., Taskinen J. Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab. Dispos. 1993, 21:81-91.
3. Wikberg T., Ottoila P., Taskinen J. Identification of major urinary metabolites of the catechol-O-methyltransferase inhibitor entacapone in the dog. Eur. J. Drug Metab. Pharmacokinet. 1993, 18:359-367.
4. Karlsson M., Wikberg T. Liquid chromatographic determination of a new catechol-O-methyltransferase inhibitor, entacapone, and its Z-isomer in human plasma and urine. J. Pharm. Biomed. Anal. 1992, 10:593-600.
5. Ramakrishna N.V.S., Vishwottam K.N., Wishu S., Koteshwara M., Chidambara J. High-performance liquid chromatography method for quantification of entacapone in human plasma. J. Chromatogr. B 2005, 823:189-194.
6. Paim C.S., Gonçalves H.M., Miron D., Sippel J., Steppe M. Stability-indicating LC determination of entacapone in tablets. Chromatographia 2007, 65:595-599.
7. Doshi A.S., Upadhyay K.J., Menta T.N., Nanda N. Development and application of a high-performance liquid chromatographic method for the determination of in vitro drug release of levodopa, carbidopa, and entacapone from a tablet formulation. J. AOAC Int. 2009, 92:394-403.
8. Mohamed N.G., Mohamed M.S. Determination of antiparkinsonism drug entacapone. J. Chil. Chem. Soc. 2010, 55:85-89.
9. Sivasubramanian L., Lakshmi K.S., Pathuri R.R. RP-HPLC estimation of entacapone in bulk and dosage form. J. Pharm. Res. 2009, 2:1850-1851.
10. Shetty S.K., Surendranath K.V., Radhakrishnanand P., Satish J., Jogul J., Tripathi U.M. Stress degradation behavior of entacapone and development of LC stability-indicating related substance and assay method. Chromatographia 2009, 69:1189-1199.
11. USP. USP 32-NF 27, Chromagography 〈671〉. Rockville, MD, USP; 2009:227-239.
12. USP. USP 32-NF 27, Spectrophotometric Identification Tests 〈197〉. Rockville, MD, USP; 2009:130-131.
13. A.C. Moffat, M.D. Osselton, B. Widdop. Clarke's Analysis of Drugs and Poisons. London, Pharmaceutical Press, 2006 (electronic publication).